Acceleron Pharma (NASDAQ:XLRN) Is Now Covered By H.C. Wainwright. What can We Expect?

October 13, 2017 - By Linda Rogers

 Acceleron Pharma (NASDAQ:XLRN) Is Now Covered By H.C. Wainwright. What can We Expect?

Investors sentiment increased to 1.44 in Q2 2017. Its up 0.51, from 0.93 in 2017Q1. It is positive, as 16 investors sold Acceleron Pharma Inc shares while 27 reduced holdings. 17 funds opened positions while 45 raised stakes. 33.54 million shares or 7.21% more from 31.29 million shares in 2017Q1 were reported.

Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 1,024 shares. 520,057 were accumulated by Goldman Sachs Group. 28,765 are owned by Baker Bros Advsrs L P. Sg Americas Ltd invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Parallax Volatility Advisers Limited Partnership stated it has 4,672 shares. Tekla Capital Management Limited Liability Corp holds 0.07% or 59,654 shares. Principal Gp Inc reported 104,234 shares. Prtn Limited owns 64,281 shares. Loring Wolcott And Coolidge Fiduciary Llp Ma owns 337 shares. 19,880 are held by Amer Intll Inc. Rhumbline Advisers reported 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Thompson Davis And accumulated 499 shares. Royal Bancshares Of Canada reported 0% in Acceleron Pharma Inc (NASDAQ:XLRN). 138,561 were reported by Bancorporation Of New York Mellon. Tudor Et Al holds 0.01% or 12,800 shares.

Why Has H.C. Wainwright Given Acceleron Pharma (NASDAQ:XLRN) a $57 Price Target

H.C. Wainwright analyst has started coverage with a Buy rating on Acceleron Pharma (NASDAQ:XLRN) today and set a price target of $57. The firm’s shares opened today at 0.

Investors sentiment increased to 1.44 in Q2 2017. Its up 0.51, from 0.93 in 2017Q1. It is positive, as 16 investors sold Acceleron Pharma Inc shares while 27 reduced holdings. 17 funds opened positions while 45 raised stakes. 33.54 million shares or 7.21% more from 31.29 million shares in 2017Q1 were reported.

Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 1,024 shares. 520,057 were accumulated by Goldman Sachs Group. 28,765 are owned by Baker Bros Advsrs L P. Sg Americas Ltd invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Parallax Volatility Advisers Limited Partnership stated it has 4,672 shares. Tekla Capital Management Limited Liability Corp holds 0.07% or 59,654 shares. Principal Gp Inc reported 104,234 shares. Prtn Limited owns 64,281 shares. Loring Wolcott And Coolidge Fiduciary Llp Ma owns 337 shares. 19,880 are held by Amer Intll Inc. Rhumbline Advisers reported 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Thompson Davis And accumulated 499 shares. Royal Bancshares Of Canada reported 0% in Acceleron Pharma Inc (NASDAQ:XLRN). 138,561 were reported by Bancorporation Of New York Mellon. Tudor Et Al holds 0.01% or 12,800 shares.

Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Acceleron Pharma has $63 highest and $20 lowest target. $42.57’s average target is 9.63% above currents $38.83 stock price. Acceleron Pharma had 32 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) has “Hold” rating given on Tuesday, August 1 by Oppenheimer. As per Tuesday, June 13, the company rating was maintained by FBR Capital. The rating was initiated by Oppenheimer on Tuesday, December 13 with “Outperform”. Credit Suisse downgraded Acceleron Pharma Inc (NASDAQ:XLRN) rating on Thursday, September 21. Credit Suisse has “Hold” rating and $35.0 target. The rating was maintained by Barclays Capital on Wednesday, September 20 with “Overweight”. The rating was maintained by FBR Capital with “Buy” on Friday, June 23. The firm earned “Outperform” rating on Friday, November 20 by Oppenheimer. FBR Capital maintained the shares of XLRN in report on Monday, January 18 with “Outperform” rating. As per Thursday, August 13, the company rating was initiated by Morgan Stanley. The stock has “Market Perform” rating by Oppenheimer on Tuesday, June 13.

The stock decreased 0.13% or $0.05 during the last trading session, reaching $38.83. About 190,342 shares traded. Acceleron Pharma Inc (NASDAQ:XLRN) has declined 22.43% since October 13, 2016 and is downtrending. It has underperformed by 39.13% the S&P500.

Analysts expect Acceleron Pharma Inc (NASDAQ:XLRN) to report $-0.68 EPS on November, 2.They anticipate $0.13 EPS change or 23.64 % from last quarter’s $-0.55 EPS. After having $-0.77 EPS previously, Acceleron Pharma Inc’s analysts see -11.69 % EPS growth.

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.71 billion. The Firm is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. It currently has negative earnings. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta , protein superfamily.

More notable recent Acceleron Pharma Inc (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Acceleron’s Unique Pipeline Looks Undervalued” on October 12, 2017, also Businesswire.com with their article: “Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares” published on October 05, 2017, Streetinsider.com published: “Acceleron Pharma (XLRN) Prices 5.405M Common Share Offering at $37/Sh” on September 21, 2017. More interesting news about Acceleron Pharma Inc (NASDAQ:XLRN) were released by: Benzinga.com and their article: “4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate” published on October 12, 2017 as well as Streetinsider.com‘s news article titled: “Acceleron Pharma (XLRN) Plans $150M Offering of Common Stock” with publication date: September 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.